U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746713) titled 'A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer' on July 31.
Brief Summary: The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose [RP2D]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).
Study Start Date: Aug. 17
Study Type: INTERVENTIONAL
Condition:
Prostatic Neoplasms
Interventi...